Oxbow Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 105.1% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 66,949 shares of the company’s stock after acquiring an additional 34,313 shares during the period. Johnson & Johnson makes up approximately 1.2% of Oxbow Advisors LLC’s holdings, making the stock its 17th largest holding. Oxbow Advisors LLC’s holdings in Johnson & Johnson were worth $8,662,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Palouse Capital Management Inc. acquired a new position in Johnson & Johnson during the 3rd quarter worth $5,047,000. Sciencast Management LP boosted its position in Johnson & Johnson by 5.8% during the 3rd quarter. Sciencast Management LP now owns 12,170 shares of the company’s stock worth $1,612,000 after acquiring an additional 670 shares during the period. California Public Employees Retirement System boosted its position in Johnson & Johnson by 16.9% during the 3rd quarter. California Public Employees Retirement System now owns 10,198,888 shares of the company’s stock worth $1,319,532,000 after acquiring an additional 1,477,454 shares during the period. Delta Asset Management LLC TN boosted its position in Johnson & Johnson by 1.2% during the 3rd quarter. Delta Asset Management LLC TN now owns 34,325 shares of the company’s stock worth $4,441,000 after acquiring an additional 416 shares during the period. Finally, Duncker Streett & Co. Inc. boosted its position in Johnson & Johnson by 0.5% during the 3rd quarter. Duncker Streett & Co. Inc. now owns 39,291 shares of the company’s stock worth $5,083,000 after acquiring an additional 214 shares during the period. 72.25% of the stock is currently owned by institutional investors.
A number of research analysts have issued reports on JNJ shares. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Bank of America reiterated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Wells Fargo & Co reduced their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Finally, Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and an average price target of $151.64.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. During the same quarter in the prior year, the firm posted $2.05 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: How do CD ladders protect against rising interest rates?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.